Dr. Xu Tao, VP of Chemical.AI, to Speak at 2024 Biopharmaceutical Innovation Expo on AI and Automation in Drug Discovery
Chemical AI
AI Chemical Drug Developer
The 2024 Biopharmaceutical Innovation Expo features 12 forums, inviting over 200 industry experts to attend, jointly exploring cutting-edge topics and development trends in the biologics and chemical pharmaceuticals fields, sharing the latest project achievements, experiences, and strategic insights, and better empowering the development of China's pharmaceutical industry.
The organizing committee is honored to inviteDr. Xu Tao, Vice President of Chemical AIAttend2024 Biomedical Innovation ExpoAt the Small Molecule Drug Development Strategies Forum"AI + Automation Empowering New Drug Development"Give a report sharing.
Vice President of Chemical AI, dedicated to molecular simulation, CADD, and artificial intelligence fields, achieving the digitization of drug discovery, engineering, productization, and commercialization of laboratory automation, empowering life science research and biopharmaceutical R&D innovation. Currently, it has provided product technical services to more than 200 "industry-academia-research-government" customers in China.
Scan the code to register for the conference
2024 Biomedical Innovation Expo Setup12 Forums：New Drug Founders Summit, M&A and Project Collaboration, GLP1 and Peptides, Nucleic Acid Drug Development, XDC Forum, Early Development of Innovative Drugs, FDA Regulation of Emerging Medical Products, Clinical Development Forum, Small Molecule Drug Development Strategies, Academic Research Institution Innovative Drug Translation Forum, Dual Filing in China and the US for Innovative Drugs, Antibody Forum. Numerous invitations will be extended.200+ Industry ExpertsArrive to jointly discuss cutting-edge topics and development trends in the fields of biopharmaceuticals and chemical pharmaceuticals, share the latest project achievements, experiences, and strategic insights, and better empower the development of China's pharmaceutical industry.
August 15th, Hall C, Booth C104 Small Molecule Drug Development Strategies
Agenda
09:00-09:20 Development of a Novel Small Molecule Conjugate Drug Based on Molecular Glue Payload
Ren Zhihua |Kintor Pharmaceuticals, VP/Dean of the New Drug Research Institute
09:20-09:40 Global Trends in Small Molecule Drug Development (Targets, Disease Areas, Companies)
09:40-10:00 Exploration of Differentiated Pathways in GLP-1 Receptor Agonist Development
Chen Wei |Ganli Pharmaceutical, Vice General Manager
10:00-10:20 Trends in AI-Accelerated Chemical Synthesis
Li Liyan |Merck China, Digital Product Manager
10:20-10:40 The Dilemma, Challenges, and Transformation of China's Innovative Pharmaceuticals
Hu Shaojing |Sikang Ruiqi, CEO
10:40-11:00 AI + Automation Empowering New Drug Development
Xu Tao |Chemical AI, Vice President
11:00-11:20 Fast to First-in-Human (FIH) vs. Fast to Market -- Common CMC Challenges and Strategies
Huang Lianfeng |Crystal Cloud Pharmaceuticals, Chief Scientist
11:20-11:40 AI Computation-Driven Development of Allosteric Small Molecule Agonists
Shen Qiancheng |Yudao Bio, CEO
11:40-13:30 Lunch
13:30-13:50 Rediscovery of Paclitaxel: An innovative oral Paclitaxel softgel capsule product for improving cancer therapeutics
Huang Huiyu |Meiji Biotech, Chief Scientific Officer
13:50-14:10 Progress in the Development of PARP1-Specific Inhibitor Drugs
Guest Itinerary Confirmation in Progress
14:10-14:30 How to Conduct Risk Assessment in Innovative Drug Development?
Chen Hong |Specially Appointed Expert of the State Administration of Foreign Experts Affairs
14:30-14:50 Case Study on Trace Impurity Research and Platform for High-Difficulty Impurity Research
Feng Shengxi |Aiqi Xi, General Manager
14:50-15:10 Key Points in Preclinical Pharmacological Research of Drugs for Nervous System Diseases
Jiang Wanxiang |Green Technology, Vice General Manager/Institution Head
15:10-15:30 Rapid Advancement of PCC to IND: Pharmaceutical Considerations
Tang Kaiyong |Hongbo Zhiyuan, Vice President
15:30-15:50 Targeted Drugs for KRAS G12C Break the Dilemma of "Undruggable" Targets (Proposed)
Huajian Future (Guest Itinerary To Be Confirmed)
15:50-16:10 Risk Assessment and Control Strategy Considerations for Nitrosamine Drug-Related Impurities
Cao Yudong |LianBio, Head of CMC
16:10-16:30 Development of Innovative Immunotherapies for Gastrointestinal Diseases and Gastrointestinal Tumors
Hu Pingsheng |Guizhou Shenguo Biotech, CEO
Forward Welfare- After successfully registering for the conference by scanning the QR code below, you can join the group to participate in the sharing activity. Prizes such as cash red packets, coffee vouchers, fruit baskets, and even a mysterious grand prize will be randomly awarded.
● Scan to register
● Scan to join the group
Registration Benefits- The editor has compiled a summary of cutting-edge new drug literature, available for reference, with a total of 70 articles.Welcome to add V after registration: 13375768723 to claim.
▼Conference Details, Click to View
